Preliminary observations of tag shedding, tag reporting, tag wounds, and tag biofouling for raggedtooth sharks (Carcharias taurus) tagged off the east coast of South Africa

Mark-recapture models do not distinguish how ‘‘deaths’’ accrue to marked animals in the population. If animals lose their tags, then recaptures will be fewer than expected and estimates of survival will be underestimated (Arnason and Mills, 1981; McDonald et al., 2003). Similarly, if the non-reporting rate is unknown and assumed to be negligible, as is the case in some tagging studies (e.g. Cliff et al., 1996, for white sharks Carcharodon carcharias), the probability of capture can be underestimated. The effects of both these problems, inherent in cooperative tagging programmes, lead to too few tagged fish being recovered, with a positive bias on the estimation of population size. These effects are most pronounced when capture probability is low and fewer tags are available for recapture (McDonald et al., 2003)

Seasonality, behaviour and philopatry of spotted ragged-tooth sharks Carcharias taurus in Eastern Cape nursery areas, South Africa

Spotted ragged-tooth sharks Carcharias taurus occur along the southern and eastern coasts of South Africa. We report on movements of juveniles and adults within a known nursery area on the Eastern Cape coast using  acoustic telemetry. The focus area of the study was Algoa Bay, where six VEMCO VR2 ultrasonic receivers were placed at known shark aggregation sites. An additional receiver was placed at Thunderbolt Reef, approximately 2 km southwest of Cape Recife, the south-western tip of Algoa Bay. Single receivers were also deployed at Port Alfred and East London, some 45 and 170 km north-east of Algoa Bay, respectively.  VEMCO acoustic V16 tags were either surgically implanted (n = 37) or attached externally using dart heads (n = 6) between January 2003 and March 2006. Surgically implanted tags were recorded over multiple months and years, whereas external tags were probably lost shortly after tagging because they were detected for very short periods. Sharks moved extensively between the sites and revisited monitored reefs over time-periods of months and years, demonstrating philopatry. Departures from and arrivals at reefs were more frequently recorded at sunset and sunrise, respectively. Sharks were detected throughout the year but they spent more time at aggregation sites during summer and autumn, indicating seasonal abundance in agreement with previous findings. Movements away from study reefs were attributed to either foraging or movements to other reefs. Despite extensive movements around the bay and beyond, both juveniles and adults exhibited philopatry to the study area over multiple years.Keywords: acoustic telemetry, Algoa Bay, behaviour, migratio

Genomic resources for the spotted ragged-tooth shark Carcharias taurus

Genomic data can be a useful tool in the management and conservation of biodiversity. Here, we report the development of genomic resources for the spotted ragged-tooth shark Carcharias taurus using genome-wide DNA data from Illumina next-generation sequencing. We explored two commonly used genetic marker types: microsatellites and mitochondrial DNA. A total of 4 394 putative microsatellites were identified, of which 10 were tested on 24 individuals and found to have ideal properties for population genetic analyses. Additionally, we reconstructed the first complete mitochondrial genome of a South African spotted ragged-tooth shark, and highlight the most informative gene regions to facilitate future primer design. The data reported here may serve as a resource for future studies and can ultimately be applied in the sustainable conservation and fisheries management of this apex predator.Keywords: genotype, grey nurse shark, Illumina next-generation sequencing, microsatellites, mitogenome, primer design, sand tiger shar

Future research directions on the “Elusive” White Shark

White sharks, Carcharodon carcharias, are often described as elusive, with little information available due to the logistical difficulties of studying large marine predators that make long-distance migrations across ocean basins. Increased understanding of aggregation patterns, combined with recent advances in technology have, however, facilitated a new breadth of studies revealing fresh insights into the biology and ecology of white sharks. Although we may no longer be able to refer to the white shark as a little-known, elusive species, there remain numerous key questions that warrant investigation and research focus. Although white sharks have separate populations, they seemingly share similar biological and ecological traits across their global distribution. Yet, white shark’s behavior and migratory patterns can widely differ, which makes formalizing similarities across its distribution challenging. Prioritization of research questions is important to maximize limited resources because white sharks are naturally low in abundance and play important regulatory roles in the ecosystem. Here, we consulted 43 white shark experts to identify these issues. The questions listed and developed here provide a global road map for future research on white sharks to advance progress toward key goals that are informed by the needs of the research community and resource managers

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society